BioRestorative Therapies, Inc.(BRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BRTX BioRestorative Therapies, Inc.

盘后交易 08-12 19:45:38 EDT

0.2123

+0.0023

+1.10%

盘后0.2204

+0.0081+3.82%

17:13 EDT

最高0.2250	最低0.2111	成交量34.65万
今开0.2167	昨收0.2100	日振幅6.62%
总市值540.90万	流通市值513.24万	总股本2,548万
成交额7.59万	换手率1.43%	流通股本2,418万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BRTX","market":"US","secType":"STK","nameCN":"BioRestorative Therapies, Inc.","latestPrice":0.2123,"timestamp":1786564800000,"preClose":0.21,"halted":0,"volume":346521,"hourTrading":{"tag":"盘后","latestPrice":0.2204,"preClose":0.2123,"latestTime":"17:13 EDT","volume":337,"amount":75.17010453,"timestamp":1786569198918,"change":0.0081,"changeRate":0.038154,"amplitude":0.059821},"delay":0,"changeRate":0.010952380952380936,"floatShares":24175300,"shares":25478200,"eps":-1.0878,"marketStatus":"盘后交易","change":0.0023,"latestTime":"08-12 19:45:38 EDT","open":0.2167,"high":0.225,"low":0.2111,"amount":75890.58009036,"amplitude":0.06619,"askPrice":0.23,"askSize":335,"bidPrice":0.22,"bidSize":2005,"shortable":3,"etf":0,"ttmEps":-1.0878,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786579200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.21,"preHourTrading":{"tag":"盘前","latestPrice":0.225,"preClose":0.21,"latestTime":"09:29 EDT","volume":7914,"amount":1726.48373496,"timestamp":1786541356738,"change":0.015,"changeRate":0.071429,"amplitude":0.093333},"postHourTrading":{"tag":"盘后","latestPrice":0.2204,"preClose":0.2123,"latestTime":"17:13 EDT","volume":337,"amount":75.17010453,"timestamp":1786569198918,"change":0.0081,"changeRate":0.038154,"amplitude":0.059821},"volumeRatio":1.353875},"requestUrl":"/m/hq/s/BRTX","defaultTab":"news","newsList":[{"id":"1133876075","title":"BioRestorative Therapies 高管变动：Lance Alstodt 辞去所有职务，7月13日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1133876075","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133876075?lang=zh_cn&edition=full","pubTime":"2026-07-17 05:38","pubTimestamp":1784237920,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会（SEC）提交的文件，BioRestorative Therapies, Inc. 公司宣布，Lance Alstodt 已辞去公司总裁、首席执行官、董事会主席及所有其他职务，该决定自2026年7月13日起生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100895780","title":"BioRestorative Therapies首席财务官罗伯特·克里斯特尔将于2026年7月13日辞去所有职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1100895780","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100895780?lang=zh_cn&edition=full","pubTime":"2026-07-17 05:38","pubTimestamp":1784237920,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的文件，BioRestorative Therapies, Inc.公司首席财务官罗伯特·克里斯特尔已提交辞呈。其辞去首席财务官及在公司内担任的所有其他职务将于2026年7月13日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137816998","title":"BioRestorative Therapies任命Katharyn Field为首席执行官、总裁兼临时首席财务官，自2026年7月13日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1137816998","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137816998?lang=zh_cn&edition=full","pubTime":"2026-07-17 05:38","pubTimestamp":1784237920,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，生物修复疗法公司（BioRestorative Therapies, Inc.）已任命凯瑟琳·菲尔德（Katharyn Field）担任首席执行官、总裁及临时首席财务官，该任命将于2026年7月13日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159815510","title":"BioRestorative Therapies任命医疗高管Zach Smith为生物化妆品部门副总裁，以强化领导层并加速商业扩张与战略增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1159815510","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159815510?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:16","pubTimestamp":1781784991,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc.（BRTX）宣布任命医疗行业资深人士Zachary Smith担任其生物化妆品部门副总裁。这一关键人事任命旨在加强公司领导团队实力，从而加速该部门的商业扩张步伐与整体战略增长。Smith先生将负责推动生物化妆品业务线的商业化进程，并制定与执行长期增长战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187882777","title":"Kaos Capital紧急寻求与BioRestorative Therapies董事会会面 共商释放股东价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1187882777","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187882777?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:47","pubTimestamp":1779882469,"startTime":"0","endTime":"0","summary":"Kaos Capital正急切寻求与BioRestorative Therapies, Inc.（简称BioRestorative Therapies）董事会举行会议，旨在探讨如何有效释放公司股东价值。这一举措凸显了该投资机构对BioRestorative Therapies当前发展状况与未来潜力的高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116033280","title":"BioRestorative Therapies公司：52周时52%的患者在VAS疼痛与ODI功能上实现≥50%改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1116033280","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116033280?lang=zh_cn&edition=full","pubTime":"2026-05-08 00:01","pubTimestamp":1778169677,"startTime":"0","endTime":"0","summary":"一项为期52周的临床研究数据显示，BioRestorative Therapies公司在其疗法试验中取得了显著成效。结果显示，超过半数的受试者——具体比例为52%——在视觉模拟量表疼痛评分和Oswestry功能障碍指数评估中，其改善幅度均达到或超过了50%的阈值。这一积极成果凸显了该疗法在缓解患者疼痛和提升功能恢复方面的潜在效力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138202377","title":"BioRestorative Therapies公司52周队列增至25名患者，未出现剂量限制性毒性安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1138202377","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138202377?lang=zh_cn&edition=full","pubTime":"2026-05-08 00:01","pubTimestamp":1778169674,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies公司宣布，其临床研究的52周队列规模已扩大至25名患者。令人鼓舞的是，截至目前，该队列中仍未观察到任何剂量限制性毒性的安全信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182980307","title":"BioRestorative Therapies公布BRTX-100二期盲法扩展数据集 显示慢性腰椎间盘疾病疼痛与功能持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1182980307","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182980307?lang=zh_cn&edition=full","pubTime":"2026-05-08 00:01","pubTimestamp":1778169671,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies公司发布了其主打疗法BRTX-100在二期临床试验中的扩展盲法数据集。最新数据表明，该疗法在治疗慢性腰椎间盘疾病方面展现出持续性的疼痛缓解与功能改善效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115530780","title":"BioRestorative Therapies宣布与203 Creates达成战略合作，共同构建并商业化生物化妆品平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1115530780","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115530780?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:18","pubTimestamp":1775564322,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc. 已正式宣布与203 Creates建立战略合作伙伴关系。双方将携手共建并推动其生物化妆品平台的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158746491","title":"BioRestorative Therapies公司宣布：低氧培养间充质干细胞未出现与剂量限制性毒性相关的不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1158746491","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158746491?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:07","pubTimestamp":1774872424,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc. 近日公布了一项重要进展。在其针对低氧培养间充质干细胞的研究中，未观察到任何与剂量限制性毒性相关的不良事件。这一发现为相关疗法的安全性提供了积极数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175866199","title":"BioRestorative Therapies公布BRTX-100二期盲态积极数据，显示慢性腰椎间盘疾病患者疼痛与功能获得显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1175866199","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175866199?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:06","pubTimestamp":1774872407,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc. (以下简称\"BioRestorative Therapies\")近日公布了其主打候选产品BRTX-100在二期临床试验中的盲态数据。数据显示，该疗法在治疗慢性腰椎间盘疾病方面，为患者的疼痛缓解和功能恢复带来了具有临床意义的改善。\n此次公布的盲态数据结果令人鼓舞，表明BRTX-100有潜力成为治疗这一困扰众多患者的慢性疾病的重要新选择。公司将继续推进该疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170171854","title":"BioRestorative Therapies公布BRTX-100二期数据：超半数患者改善程度逾50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170171854","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170171854?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:03","pubTimestamp":1774872192,"startTime":"0","endTime":"0","summary":"再生疗法公司BioRestorative Therapies, Inc.近日披露了其主打候选产品BRTX-100的二期临床试验数据。数据显示，在接受治疗的受试者中，有超过50%的患者其关键指标获得了超过50%的显著改善。这一积极结果标志着该疗法在针对特定适应症的开发进程中取得了重要进展，为公司后续的临床研究和商业化布局奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102433433","title":"BioRestorative Therapies, Inc.扩大Thermostem®全球保护范围，该细胞疗法或成GLP-1药物更长效、更安全的替代方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1102433433","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102433433?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:35","pubTimestamp":1771940125,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc.正在强化其创新疗法Thermostem®的全球知识产权保护布局。该细胞疗法有望成为GLP-1类药物的一种新型替代方案，其特点在于可能具备更持久的疗效和更高的安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613750695","title":"Biorestorative Therapies, Inc.盘中异动 股价大跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613750695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613750695?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:31","pubTimestamp":1771857080,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时31分，Biorestorative Therapies, Inc.股票出现波动，股价大幅下跌5.35%。Biorestorative Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Arcellx, Inc.、Vanda Pharmaceuticals Inc.、传奇生物涨幅较大，Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.、Fortress Biotech, Inc.较为活跃，换手率分别为174.79%、31.25%、25.43%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc.、Camp4 Therapeutics Corporation、Aspire Biopharma Holdings, Inc.，振幅分别为11.46%、9.68%、9.50%。Biorestorative Therapies, Inc.公司简介：BioRestorative Therapies Inc是一家总部位于美国的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223120a71631bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223120a71631bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612236552","title":"Biorestorative Therapies, Inc.盘中异动 急速下跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612236552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2612236552?lang=zh_cn&edition=full","pubTime":"2026-02-19 23:24","pubTimestamp":1771514664,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日23时24分，Biorestorative Therapies, Inc.股票出现异动，股价快速下挫5.04%。Biorestorative Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Cingulate Inc C/Wts 10/12/2026 、Moolec Science Sa涨幅较大，Enveric Biosciences, Inc.、Pmgc Holdings Inc.、Theriva Biologics, Inc.较为活跃，换手率分别为1145.19%、704.43%、649.00%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Theriva Biologics, Inc.，振幅分别为247.75%、51.67%、23.39%。Biorestorative Therapies, Inc.公司简介：BioRestorative Therapies Inc是一家总部位于美国的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923242595417905&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923242595417905&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106029431","title":"BioRestorative宣布与FDA B类会议取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1106029431","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106029431?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:56","pubTimestamp":1770814603,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies Inc 公布其与美国食品药品监督管理局（FDA）举行的B类会议结果积极。\n该公司目前预期将于2026年下半年提交三期临床试验的新药研究申请。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180857056","title":"BioRestorative Therapies公司预计三期临床试验新药申请将于2026年下半年提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1180857056","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180857056?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:31","pubTimestamp":1770813070,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies公司近日更新了其核心研发管线的时间表。该公司目前预期，其备受关注的三期临床试验的新药研究申请（IND），计划在2026年下半年正式提交。这一进展标志着其在研疗法向商业化迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610672488","title":"Biorestorative Therapies, Inc.股价重挫18.29% 市值跌138.62万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2610672488?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:32","pubTimestamp":1770733936,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时32分，Biorestorative Therapies, Inc.股票出现异动，股价大幅下挫18.29%。截至发稿，该股报0.854美元/股，成交量2.2527万股，换手率0.25%，振幅4.25%。Biorestorative Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Quince Therapeutics, Inc.、Evommune, Inc.、Abpro Holdings, Inc涨幅较大，Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃，换手率分别为982.33%、620.36%、424.96%，振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Tectonic Therapeutic, Inc.，振幅分别为21.31%、15.79%、10.43%。Biorestorative Therapies, Inc.公司简介：BioRestorative Therapies Inc是一家总部位于美国的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223216a6eaf7f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223216a6eaf7f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189170413","title":"BioRestorative Therapies, Inc. 完成慢性腰椎间盘疾病创新疗法Brtx-100的里程碑式二期临床试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1189170413","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189170413?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:03","pubTimestamp":1770728625,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc. 已成功完成其针对慢性腰椎间盘疾病的候选疗法Brtx-100在二期临床试验中的患者招募工作。这一进展标志着该疗法在临床开发道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517940515","title":"Biorestorative Therapies, Inc.盘中异动 大幅上涨5.59%报1.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940515","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517940515?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:27","pubTimestamp":1741195676,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时27分，Biorestorative Therapies, Inc.股票出现波动，股价大幅上涨5.59%。Biorestorative Therapies, Inc.股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为935.40%、303.89%、292.29%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Biorestorative Therapies, Inc.公司简介：BioRestorative Therapies Inc 是一家总部位于美国的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012756963b03bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306012756963b03bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biorestorative.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.3913},{"period":"3month","weight":0.129},{"period":"6month","weight":-0.1446},{"period":"1year","weight":-0.8511},{"period":"ytd","weight":-0.8213}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biorestorative医疗公司于1997年6月13日在内华达州注册成立。该公司目前正在开展Disc/Spine计划，初步研究治疗产品被称为BRTX-100。2022年3月，在Disc/Spine Program中发布了一项美国专利。该公司向美国食品药品监督管理局（FDA）提交了一份IND申请，以获得授权开始一项2期临床试验，调查使用BRTX-100治疗退行性椎间盘疾病引起的慢性下背痛。该公司已获得FDA的此类授权，并已开始此类临床试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.012358},{"month":2,"riseRate":0.375,"avgChangeRate":-0.14062},{"month":3,"riseRate":0.5,"avgChangeRate":0.061423},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.089618},{"month":5,"riseRate":0.25,"avgChangeRate":0.057757},{"month":6,"riseRate":0.25,"avgChangeRate":-0.054932},{"month":7,"riseRate":0.25,"avgChangeRate":-0.164737},{"month":8,"riseRate":0.5,"avgChangeRate":-0.031559},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.092188},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.096202},{"month":11,"riseRate":0.125,"avgChangeRate":8.440161},{"month":12,"riseRate":0.25,"avgChangeRate":-0.213868}],"exchange":"NASDAQ","name":"BioRestorative Therapies, Inc.","nameEN":"BioRestorative Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioRestorative Therapies, Inc.(BRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioRestorative Therapies, Inc.(BRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioRestorative Therapies, Inc.,BRTX,BioRestorative Therapies, Inc.股票,BioRestorative Therapies, Inc.股票老虎,BioRestorative Therapies, Inc.股票老虎国际,BioRestorative Therapies, Inc.行情,BioRestorative Therapies, Inc.股票行情,BioRestorative Therapies, Inc.股价,BioRestorative Therapies, Inc.股市,BioRestorative Therapies, Inc.股票价格,BioRestorative Therapies, Inc.股票交易,BioRestorative Therapies, Inc.股票购买,BioRestorative Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioRestorative Therapies, Inc.(BRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioRestorative Therapies, Inc.(BRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}